Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Operating Income: 2010-2024

Historic Operating Income for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to -$103.2 million.

  • Altimmune's Operating Income rose 15.78% to -$20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.5 million, marking a year-over-year increase of 19.18%. This contributed to the annual value of -$103.2 million for FY2024, which is 7.55% down from last year.
  • As of FY2024, Altimmune's Operating Income stood at -$103.2 million, which was down 7.55% from -$95.9 million recorded in FY2023.
  • Over the past 5 years, Altimmune's Operating Income peaked at -$54.8 million during FY2020, and registered a low of -$103.2 million during FY2024.
  • Its 3-year average for Operating Income is -$95.6 million, with a median of -$95.9 million in 2023.
  • In the last 5 years, Altimmune's Operating Income crashed by 155.29% in 2020 and then climbed by 9.47% in 2022.
  • Altimmune's Operating Income (Yearly) stood at -$54.8 million in 2020, then plummeted by 76.85% to -$96.9 million in 2021, then climbed by 9.47% to -$87.7 million in 2022, then declined by 9.33% to -$95.9 million in 2023, then decreased by 7.55% to -$103.2 million in 2024.